  | 
            
              
                
                	
                  
				English
 | 
正體中文
 | 
简体中文
 | 
					
                  	
                  	
                  	
	全文筆數/總筆數 : 18288/20515 (89%)
	
	
 
	造訪人次 : 21158588
    
	線上人數 : 1752
                  	
                  	
					 
                    | 
                 
               
              | 
          
          
             | 
          
        
		
			
			
				
				
				
				
		
				
				
		
		
            
            
    
        
            
            
資料載入中..... 
			
             | 
         
     
 
 
    
    
    
    
        
            
                
                請使用永久網址來引用或連結此文件:
                https://ir.cnu.edu.tw/handle/310902800/28693
             | 
         
     
    
    
    
 
| 標題:  | Serum Vascular Adhesion Protein-1 Level Predicts Risk of Incident Cancers in Subjects with Type II Diabetes |  
| 作者:  | Yu, Tse-Ya Li, Hung-Yuan Jiang, Yi-Der Chang, Tien-Jyun Wei, Jung-Nan Lin, Chi-Ming Chu, Ching-Chi Chuang, Lee-Ming |  
| 貢獻者:  | 職業安全衛生系 |  
| 關鍵字:  | CHRONIC KIDNEY-DISEASE SENSITIVE AMINE OXIDASE COLORECTAL-CANCER PROSTATE-CANCER INFLAMMATION ASSOCIATION PROGRESSION MORTALITY METASTASES MOLECULE |  
| 日期:  | 2014-07 |  
| 上傳時間:  | 2015-05-06 21:25:23  (UTC+8) |  
| 出版者:  | Amer Assoc Cancer Research |  
| 摘要:  | Background: Serum vascular adhesion protein-1 (VAP-1) predicts cancer-related mortality in diabetic subjects. However, whether serum VAP-1 predicts cancer incidence or cancer progression remains unclear. We conducted a cohort study to investigate whether serum VAP-1 and related clinical variables predict incident cancers in type II diabetic subjects. Methods: From 1996 to 2003, we enrolled 568 type II diabetic subjects who were free of cancer at baseline. Serum VAP-1 at enrollment was measured by time-resolved immunofluorometric assay. Chronic kidney disease (CKD) was defined as estimated glomerular filtration rate <60 mL/min per 1.73 m(2). The subjects were followed until first occurrence of cancer or until December 31, 2011. Results: During a mean follow-up of 11.3 years, 71 subjects developed incident cancers. The HRs for incident cancers in subjects with highest tertile of serum VAP-1 and in subjects with CKD were 2.95 [95% confidence interval (CI), 1.31-6.63; P = 0.009] and 2.29 (95% CI, 1.18-4.44; P = 0.015), respectively, after multivariate adjustment. There was an interaction between serum VAP-1 and CKD on the risk of incident cancers (P = 0.01 for log-transformed VAP-1 x CKD). The relationship among serum VAP-1, CKD, and incident cancers was similar if death was considered in the competing risk models or if subjects with shorter follow-up period were excluded. Conclusions: Higher serum VAP-1 and CKD can independently predict future development of cancers in type II diabetic subjects. Impact: Physicians should be aware of the early signs of cancer in diabetic individuals with elevated VAP-1 or renal dysfunction. More aggressive treatment strategies might be considered. (C)2014 AACR. |  
| 關聯:  | Cancer Epidemiology Biomarkers & Prevention, v.23 n.7, pp.1366-1373 |  
| 顯示於類別: | [職業安全衛生系(含防災所)] 期刊論文
  |  
 
文件中的檔案: 
| 檔案 | 
描述 | 
大小 | 格式 | 瀏覽次數 |  
| index.html |  | 0Kb | HTML | 2704 | 檢視/開啟 |   
 |   
    
    
     
    
    
    在CNU IR中所有的資料項目都受到原著作權保護. 
     
    
	    
     
    
    
                    
                 
                
                  |